LIGHT CHAIN (AL) AMYLOIDOSIS
Clinical trials for LIGHT CHAIN (AL) AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new LIGHT CHAIN (AL) AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for LIGHT CHAIN (AL) AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on rare protein disease in major trial
Disease control Not yet recruitingThis phase 3 trial compares an experimental CAR-T cell therapy, NXC-201, with a standard drug combination (daratumumab plus CyBorD) in people newly diagnosed with AL amyloidosis, a rare condition where abnormal proteins damage organs. Participants receive either a single infusion…
Matched conditions: LIGHT CHAIN (AL) AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Nexcella Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a deeper cleanup beat amyloidosis?
Knowledge-focused Not yet recruitingThis study looks at 50 adults with AL amyloidosis who achieved complete remission after initial chemotherapy. It checks if tiny amounts of remaining disease (called minimal residual disease, or MRD) affect organ recovery and survival. Researchers also test whether a stem cell tra…
Matched conditions: LIGHT CHAIN (AL) AMYLOIDOSIS
Phase: NA • Sponsor: Peking University First Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC